Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium (NiCCC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02866370
Recruitment Status : Recruiting
First Posted : August 15, 2016
Last Update Posted : August 15, 2016
Sponsor:
Collaborators:
Boehringer Ingelheim
Cancer Research UK
European Organisation for Research and Treatment of Cancer - EORTC
Nordic Society for Gynaecologic Oncology
ARCAGY/ GINECO GROUP
Information provided by (Responsible Party):
NHS Greater Glasgow and Clyde

Brief Summary:
The trial will recruit up to 120 patients; 90 with ovarian clear cell carcinoma and up to 30 with endometrial clear cell carcinoma. Patients will be randomised between chemotherapy and Nintedanib 200mg twice daily oral administration (PO) continuously. The primary diagnosis must be histologically confirmed and central pathological review of the presenting tumour or biopsy of relapsed disease must find at least 50% clear cell carcinoma with no serous differentiation

Condition or disease Intervention/treatment Phase
Ovarian Clear Cell Carcinoma Endometrial Clear Cell Carcinoma Drug: Nintedanib Drug: Paclitaxel Drug: Pegylated Liposomal Doxorubicin (PLD) Drug: Topotecan Drug: Carboplatin Drug: Doxorubicin Phase 2

Detailed Description:

Clear cell carcinoma (CCC) is an uncommon histotype of ovarian and a rare histotype of endometrial cancer. The prognosis for recurrent disease is poor with response rates to standard chemotherapy of <10% so there is an urgent need for novel therapies. Ovarian CCC (OCCC) is biologically different from other ovarian cancer histotypes but shares features with renal CCC, including upregulation of angiogenesis pathways. Hence inhibition of angiogenesis, which has been a successful strategy in renal CCC, may also be of benefit in OCCC and endometrial CCC (ECCC).

Nintedanib is a well-tolerated, potent, orally-available, kinase inhibitor targeting Vascular Endothelial Growth Factor (VEGFR) 1-3, Platelet Derived Growth Factor Receptor (PDGFR)α/β, and Firbroblas Gworth Factor Receptors (FGFR) 1-3. It is licensed in Europe in combination with docetaxel after first line chemotherapy for Non-Small Cell Lung Cancer (NSCLC). Importantly it also has significant activity as a single agent in renal CCC with an Overall Response Rate (ORR) of 20.3%, disease control rate of 76.% and 43% 9 month progression free survival.

Response rates (RR) of ovarian CCC to standard chemotherapy with or without platinum are poor whatever line of treatment. A number of different agents are used in recurrent CCC and, although isolated instances of response to a variety of agents have been reported, no regimen seems to offer a particular advantage. As a result the investigators do not expect to see significant differences in response rates within the chemotherapy arms of the study. Hence it is feasible to allow physicians a choice of chemotherapy from a pre-specified selection and to include patients with multiple previous relapses. Since overall and progression free survival may be shorter with successive lines of treatment, the number of previous lines of treatment will be a stratification factor. These measures should maximise recruitment of this rare tumour sub-type across different countries.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomised Phase II Study Of Nintedanib (BIBF1120) Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium
Study Start Date : April 2015
Estimated Primary Completion Date : March 2020
Estimated Study Completion Date : March 2021


Arm Intervention/treatment
Experimental: Nintedanib
Nintedanib (BIBF1120) 200mg twice daily PO, continuously
Drug: Nintedanib
Nintedanib (BIBF1120) 200mg twice daily PO, continuously, until progression or withdrawal from the treatment.
Other Names:
  • BIBF 1120
  • Vargatef

Active Comparator: Chemotherapy

Ovarian Cancer Patients:

Paclitaxel (80mg/m2) IV Day 1, 8, 15 every 28 days Pegylated Liposomal Doxorubicin (PLD) (40mg/m2) IV every 28 days Topotecan (4mg/m2) IV Day 1, 8, 15 every 28 days

Endometrial Cancer Patients:

Carboplatin (AUC 5) and Paclitaxel (175mg/m2) IV every 21 days Doxorubicin IV (60mg/m2) every 21 days

Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity. The maximal lifetime cumulative dose of doxorubicin or pegylated liposomal doxorubicin allowed is 450 mg/m2.

Drug: Paclitaxel

Ovarian Cancer Patients Paclitaxel (80mg/m2) IV Day 1, 8, 15 every 28 days* Endometrial Cancer Patients Carboplatin (AUC 5) and Paclitaxel (175mg/m2) IV every 21 days*

* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity.


Drug: Pegylated Liposomal Doxorubicin (PLD)

Ovarian Cancer Patients Pegylated Liposomal Doxorubicin (PLD) (40mg/m2) IV every 28 days*

* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity. The maximal lifetime cumulative dose of doxorubicin or pegylated liposomal doxorubicin allowed is 450 mg/m2.

Other Name: Caelyx

Drug: Topotecan

Ovarian Cancer Patients Topotecan 4mg/m2 IV Day 1, 8, 15 every 28 days*

* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity.

Other Name: Hycamtin

Drug: Carboplatin

Endometrial Cancer Patients Carboplatin (AUC 5) and Paclitaxel (175mg/m2) IV every 21 days*

* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity.


Drug: Doxorubicin

Endometrial Cancer Patients Doxorubicin IV 60mg/m2 every 21 days*

* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity. The maximal lifetime cumulative dose of doxorubicin or pegylated liposomal doxorubicin allowed is 450 mg/m2.





Primary Outcome Measures :
  1. Progression Free Survival (PFS) [ Time Frame: from date of randomisation to date of progression or death, which ever occurs earlier. Assessed up to 5 years 3 months ]
    To estimate the progression free survival (PFS) in women with relapsed clear cell carcinoma of the ovary, peritoneum or fallopian tube treated with Nintedanib and compare this to PFS in women treated with chemotherapy.


Secondary Outcome Measures :
  1. Overall Survival [ Time Frame: defined as the number of days from date of randomisation to date of death (irrespective of reason). Assessed up to 5 years 3 months ]
    To estimate overall survival in women with relapsed clear cell carcinoma of the ovary, peritoneum or fallopian tube treated with Nintedanib and compare this to OS in women treated with chemotherapy.

  2. Disease control rate [ Time Frame: 12 weeks ]
    Disease control rate (Complete response, partial response and stable disease) at 12 weeks

  3. Quality of Life (QoL) [ Time Frame: up to 5 years ]
    Measured by EORTC QLQ C30 (EORTC Quality of Life Questionnaire Core 30) questionnaire. To assess quality of life in women with relapsed clear cell carcinoma of the ovary, peritoneum or fallopian tube and endometrium treated with Nintedanib and compare this to women treated with chemotherapy.

  4. Quality of Life (QoL) [ Time Frame: up to 5 years ]
    Measured by EORTC OV28 (Ovarian Cancer Module) questionnaire. To assess quality of life in women with relapsed clear cell carcinoma of the ovary, peritoneum or fallopian tube and endometrium treated with Nintedanib and compare this to women treated with chemotherapy.

  5. Quality of Life - recent symptoms of disease and treatment [ Time Frame: up to 5 years ]
    Measured by (Measure of Ovarian Cancer Symptoms and Treatment Concerns) MOST - Recent questionnaire. To measure recent symptoms of disease and treatment in women with relapsed clear cell carcinoma of the ovary, peritoneum or fallopian tube and endometrium treated with Nintedanib and compare this to women treated with chemotherapy.

  6. Q-TWIST (Quality-Adjusted Time Without Symptoms of Disease or Toxicity of Treatment) [ Time Frame: up to 5 years ]
    Measured by EuroQol Group questionnaire EQ-5D. Q-TWiST (Quality-Adjusted Time Without Symptoms of Disease or Toxicity of Treatment) will balance quality and quantity of time by combining survival data with EQ-5D quality of life data. Periods of time spent in ill health due to treatment toxicity or disease symptoms are weighted by average EQ-5D to give a quality of life adjusted time which is combined with a similarly adjusted time spent without either toxicity or symptoms

  7. Response Rate [ Time Frame: up to 2 years ]
    To estimate response rate (RR) in women with relapsed clear cell carcinoma of the endometrium treated with Nintedanib and those treated with chemotherapy. Best response rate will be determined according to a combined GCIG criteria and RECIST criteria Version 1.1

  8. Toxicity [ Time Frame: median 12 months ]
    Adverse event data will be collected during the treatment phase of the study. This will be coded and graded as per NCI-CTCAE v4.0. At the end of treatment, all patients presenting with grade 2 or above toxicities are assessed every 4 weeks until resolution of the toxicity or until another cancer treatment is administered.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Progressive or recurrent ovarian peritoneal or fallopian tube clear cell carcinoma, or progressive or recurrent endometrial clear cell carcinoma. The primary diagnosis must be histologically confirmed and central pathological review of the presenting tumour or biopsy of relapsed disease must find at least 50% clear cell carcinoma with no serous differentiation. Progressive disease as defined by Response Evaluation Criteria in Solid Tumours (RECIST) 1.1.
  2. Failure after ≥1 prior platinum containing regimen which may have been given in the adjuvant setting. For patients with ovarian clear cell carcinoma, progression must have occurred within 6 calendar months of their last platinum dose.
  3. ECOG (Eastern Cooperative Oncology Group) Performance status of ≤2.
  4. Life expectancy of >3 months.
  5. Adequate hepatic, bone marrow coagulation and renal function

    1. Hepatic function: total bilirubin < Upper Limit of Normal (ULN); ALT and AST < 2.5 x ULN
    2. Coagulation parameters: INR (International Normalised Ratio) <2 x ULN and prothrombin time and activated partial thromboplastin time < 1.5 x ULN in the absence of therapeutic anticoagulation
    3. absolute neutrophil count (ANC) ≥ 1.5 x 109/L
    4. platelets ≥ 100 x 109L
    5. haemoglobin ≥ 9.0 g/dL
    6. proteinuria < grade 2 CTCAE (version 4)
    7. Glomerular Filtration Rate ≥40ml/min. (calculated using the Wright, Cockroft & Gault equation or measured by EDTA clearance)
  6. Female and > 18 years of age.
  7. Signed and dated written informed consent prior to admission to the study in accordance with International Conference on Harmonization on Good Clinical Practice (ICH-GCP) guidelines and local legislation.
  8. Willingness and ability to comply with scheduled visits, treatment plans and laboratory tests and other study procedures.

Exclusion Criteria:

  1. Prior treatment with Nintedanib or other angiogenesis inhibitor/VEGF targeted therapy, except for prior treatment with bevacizumab which is permitted.
  2. Treatment within 28 days prior to randomisation with any investigational drug, radiotherapy, immunotherapy, chemotherapy, hormonal therapy or biological therapy. Palliative radiotherapy may be permitted for symptomatic control of pain from bone metastases in extremities, provided that the radiotherapy does not affect target lesions, and the reason for the radiotherapy does not reflect progressive disease.
  3. Previous treatment with the chemotherapy regimen selected as the control arm by the investigator. (Prior therapy with paclitaxel given on a three weekly regimen is permitted for patients receiving weekly paclitaxel. Prior treatment with weekly paclitaxel is permitted where this has been used as part of first line therapy and it is greater than 6 months since the last dose of weekly paclitaxel. Prior weekly paclitaxel for relapsed disease is not permitted).
  4. Other malignancy diagnosed within 5 years of enrolment except for:

    1. non-melanomatous skin cancer (if adequately treated)
    2. cervical carcinoma in situ (if adequately treated)
    3. carcinoma in situ of the breast (if adequately treated)
    4. For patients with ovarian clear cell cancer, prior or synchronous endometrial cancer (if adequately treated), provided all of the following criteria are met:

      • disease stage FIGO (International Federation of Gynecology and Obstetrics) Stage 1a (tumour invades less than one half of myometrium)
      • Grade 1 or 2
  5. Patients with any other severe concurrent disease, which may increase the risk associated with study participation or study drug administration and, in the judgement of the investigator, would make the patient inappropriate for entry into this study, including significant neurologic, psychiatric, infectious, hepatic, renal, or gastrointestinal diseases or laboratory abnormality.
  6. Symptoms or signs of gastrointestinal obstruction requiring parenteral nutrition or hydration or any other gastro-intestinal disorders or abnormalities, including difficulty swallowing, that would interfere with drug absorption.
  7. Serious infections in particular if requiring systemic antibiotic (antimicrobial, antifungal) or antiviral therapy, including known hepatitis B and/or C infection and HIV-infection.
  8. Symptomatic central nervous system (CNS) metastasis or leptomeningeal carcinomatosis.
  9. Known, uncontrolled hypersensitivity to the investigational drugs or their excipients.
  10. Hypersensitivity to Nintedanib, peanut or soya, or to any of the excipients of Nintedanib.
  11. Significant cardiovascular diseases, including uncontrolled hypertension, clinically relevant cardiac arrhythmia, unstable angina or myocardial infarction within 6 months prior to randomisation, congestive heart failure > NYHA (New York Heart Association) III, severe peripheral vascular disease, clinically significant pericardial effusion.
  12. History of major thromboembolic event, such as pulmonary embolism or proximal deep vein thrombosis, unless on stable therapeutic anticoagulation
  13. Known inherited predisposition to bleeding or thrombosis.
  14. History of a cerebral vascular accident, transient ischemic attack or subarachnoid haemorrhage within the past 6 months.
  15. History of clinically significant haemorrhage in the past 6 months.
  16. Major injuries or surgery within the past 28 days prior to start of study treatment or planned surgery during the on-treatment study period.
  17. Pregnancy or breastfeeding. Patients with preserved reproductive capacity must have a negative pregnancy test (β-HCG test in urine or serum) prior to commencing study treatment.
  18. Patients with preserved reproductive capacity, unwilling to use a medically acceptable method of contraception (see section 5.7) for the duration of the trial and for 6 months afterwards.
  19. Radiographic evidence of cavitating or necrotic tumours with invasion of adjacent major blood vessels.
  20. Any psychological, familial, sociological or geographical consideration potentially hampering compliance with the study protocol and follow up schedule; those considerations should be discussed with the patient before registration in the trial.
  21. Patients who have already received maximal lifetime dose of anthracycline or have experienced cardiac toxicity from an anthracycline should not receive doxorubicin or Paclitaxel Liposomal Doxorubicin (PLD).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02866370


Contacts
Layout table for location contacts
Contact: Claire A Lawless claire.lawless@glasgow.ac.uk

Locations
Layout table for location information
United Kingdom
Beatson West of Scotland Cancer Centre Recruiting
Glasgow, Lanarkshire, United Kingdom, G12 0YN
Contact: Ros Glasspool         
Principal Investigator: Ros Glasspool         
Sub-Investigator: Iain McNeish         
Ninewells Hospital Recruiting
Dundee, Tayside, United Kingdom
Principal Investigator: Michelle Ferguson         
Clatterbridge Cancer Centre Recruiting
Liverpool, Wirral, United Kingdom
Principal Investigator: Rosemary Lord         
Belfast City Hospital (Northern Ireland Cancer Centre) Recruiting
Belfast, United Kingdom
Principal Investigator: Sarah McKenna         
Bristol Heamatology and Cancer Centre Recruiting
Bristol, United Kingdom
Principal Investigator: Axel Walther         
Velindre Hospital Recruiting
Cardiff, United Kingdom
Principal Investigator: Rachel Jones         
Kent & Canterbury Hospital Recruiting
Kent, United Kingdom
Principal Investigator: Justin Waters         
Queen Elizabeth Queen Mother Hospital Recruiting
Kent, United Kingdom
Principal Investigator: Justin Waters         
William Harvey Hospital Recruiting
Kent, United Kingdom
Principal Investigator: Justin Waters         
St James Hospital Recruiting
Leeds, United Kingdom
Principal Investigator: Geoff Hall         
Guy's Hosital Recruiting
London, United Kingdom
Principal Investigator: Ana Montes         
Royal Marsden Hospital Recruiting
London, United Kingdom
Principal Investigator: Susannah Bannerjee         
St Bartholomew's Hospital Not yet recruiting
London, United Kingdom
Principal Investigator: Melanie Powell         
University College London Hospital Not yet recruiting
London, United Kingdom
Principal Investigator: Jonathan Ledermann         
The Christie Hospital Recruiting
Manchester, United Kingdom
Principal Investigator: Andrew Clamp         
Great Western Hospital Recruiting
Swindon, United Kingdom
Principal Investigator: Omar Khan         
Musgrove Park Hospital Recruiting
Taunton, United Kingdom
Principal Investigator: Clare Barlow         
Sponsors and Collaborators
NHS Greater Glasgow and Clyde
Boehringer Ingelheim
Cancer Research UK
European Organisation for Research and Treatment of Cancer - EORTC
Nordic Society for Gynaecologic Oncology
ARCAGY/ GINECO GROUP
Investigators
Layout table for investigator information
Principal Investigator: Rosalind Glasspool NHS Greater Glasgow and Clyde

Layout table for additonal information
Responsible Party: NHS Greater Glasgow and Clyde
ClinicalTrials.gov Identifier: NCT02866370     History of Changes
Other Study ID Numbers: GN12ON259 (NiCCC2013)
2013-002109-73 ( EudraCT Number )
ISRCTN50772895 ( Registry Identifier: ISRCTN )
ENGOT-GYN1 ( Other Identifier: ENGOT )
EORTC1212 ( Other Identifier: EORTC )
First Posted: August 15, 2016    Key Record Dates
Last Update Posted: August 15, 2016
Last Verified: July 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: It is proposed that data generated by the study will be available 2 years after completion of the trial, or after publication of the first major paper describing the dataset, whichever occurs sooner.

Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Adenomyoepithelioma
Adenocarcinoma, Clear Cell
Carcinoma, Ovarian Epithelial
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Complex and Mixed
Adenocarcinoma
Ovarian Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Paclitaxel
Albumin-Bound Paclitaxel
Carboplatin
Doxorubicin
Liposomal doxorubicin
Topotecan
Nintedanib
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents